Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Gongshu District, Hangzhou 310022, China; Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, China.
Department of Pharmacy, Zhejiang Cancer Hospital, Gongshu District, Hangzhou 310022, China.
Hum Pathol. 2018 Nov;81:105-112. doi: 10.1016/j.humpath.2018.06.016. Epub 2018 Jun 25.
Some thyroid carcinomas (TCs) have an aggressive biological behavior and poor prognosis, and lacking of effective molecular markers is still the main obstacle for clinical stratified diagnosis and treatment of TC. The aim of the study was to discover the clinicopathological and prognostic implications of Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) and Hook microtubule tethering protein 1 (Hook1) expression in TC. The expression of SHP2 and Hook1 was detected by immunohistochemistry on tissue microarrays from 313 primary TCs who underwent surgery in January 2006 and January 2010 in Zhejiang Cancer Hospital. The χ test, Kaplan-Meier method, and Cox proportional-hazards regression models were used to analyze the associations between their expressions and clinicopathological features and prognosis. The expression rates of SHP2 and Hook1 in TC were 57.5% (180/313) and 22.0% (69/313), respectively. SHP2 was positively correlated with Hook1 in TC. SHP2 expression differed significantly by age, histologic variants, maximal tumor diameter, intrathyroidal dissemination, metastases, and disease stage (P < .05). Moreover, patients with high SHP2 expression had reduced risk for death of disease compared with those with low SHP2 expression (hazard ratio, 0.267; 95% confidence interval, 0.105-0.684; P = .006) in univariate analysis, but that multivariate analysis failed to suggest that SHP2 was an independent prognostic factor. Hook1 expression differed significantly by histologic variants, maximal tumor diameter, and intrathyroidal dissemination (P < .05). However, there was no significant correlation between Hook1 expression and outcome in TC (P > .05). Our results suggested that SHP2 may be a favorable indicator of prognosis in TC.
一些甲状腺癌 (TC) 具有侵袭性的生物学行为和较差的预后，缺乏有效的分子标志物仍然是 TC 临床分层诊断和治疗的主要障碍。本研究旨在探讨 Src 同源结构域 2 含蛋白酪氨酸磷酸酶 2 (SHP2) 和 Hook 微管连接蛋白 1 (Hook1) 在 TC 中的表达与临床病理和预后的关系。采用免疫组织化学方法检测 2006 年 1 月至 2010 年 1 月在浙江省肿瘤医院接受手术治疗的 313 例原发性 TC 组织微阵列中 SHP2 和 Hook1 的表达。采用 χ2 检验、Kaplan-Meier 法和 Cox 比例风险回归模型分析其表达与临床病理特征和预后的关系。TC 中 SHP2 和 Hook1 的表达率分别为 57.5%（180/313）和 22.0%（69/313）。TC 中 SHP2 与 Hook1 呈正相关。SHP2 表达与年龄、组织学变异型、最大肿瘤直径、甲状腺内播散、转移和疾病分期显著相关（P<0.05）。此外，在单因素分析中，高 SHP2 表达患者的疾病死亡风险较 SHP2 低表达患者降低（风险比，0.267；95%置信区间，0.105-0.684；P=0.006），但多因素分析提示 SHP2 不是独立的预后因素。Hook1 表达与组织学变异型、最大肿瘤直径和甲状腺内播散显著相关（P<0.05）。然而，在 TC 中，Hook1 表达与预后无显著相关性（P>0.05）。我们的结果表明，SHP2 可能是 TC 预后的一个有利指标。
